Cvots | List of Frontiers open access articles

Mini Review

Published on 08 Dec 2023

The benefits of GLP1 receptors in cardiovascular diseases

in Diabetes Cardiovascular Complications

Lamija Ferhatbegović
Denis Mršić
Amra Macić-Džanković

Frontiers in Clinical Diabetes and Healthcare

doi 10.3389/fcdhc.2023.1293926

53,770 views
96 citations

Perspective

Published on 07 Dec 2021

SGLT2is vs. GLP1RAs Reduce Cardiovascular and All-Cause Mortality

in General Cardiovascular Medicine

Mei Qiu
Xu-Bin Wei
Wei Wei

Frontiers in Cardiovascular Medicine

doi 10.3389/fcvm.2021.791311

4,017 views
7 citations

Review

Published on 24 Apr 2024

Glucagon-like peptide-1 receptor agonists: new strategies and therapeutic targets to treat atherosclerotic cardiovascular disease

in Cardiovascular and Smooth Muscle Pharmacology

Tianyu Wang
Juncan Ding
Xinyi Cheng
Qiang Yang
Pengfei Hu

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1396656

6,709 views
11 citations

Review

Published on 20 Sep 2022

The potential of glucagon-like peptide-1 receptor agonists in heart failure

in Clinical and Translational Physiology

Frederik Flindt Kreiner
G. Kees Kornelis Hovingh
Bernt Johan von Scholten

Frontiers in Physiology

doi 10.3389/fphys.2022.983961

10,286 views
14 citations

Systematic Review

Published on 03 Jul 2023

Exploring the comparative cardiovascular death benefits of sodium–glucose cotransporter 2 inhibitors in type 2 diabetes: a frequentist and Bayesian network meta-analysis-based scoring

in Clinical Diabetes

Samit Ghosal
Binayak Sinha

Frontiers in Endocrinology

doi 10.3389/fendo.2023.1168755

6,180 views
6 citations

Original Research

Published on 26 May 2022

Exposure–Response Analysis of Cardiovascular Outcome Trials With Incretin-Based Therapies

in Cellular Endocrinology

Qi Pan
Mingxia Yuan
Lixin Guo

Frontiers in Endocrinology

doi 10.3389/fendo.2022.893971

4,045 views
8 citations

Review

Published on 01 Dec 2020

The Effects of DPP-4 Inhibitors, GLP-1RAs, and SGLT-2/1 Inhibitors on Heart Failure Outcomes in Diabetic Patients With and Without Heart Failure History: Insights From CVOTs and Drug Mechanism

in Clinical Diabetes

Xiaohui Pan
Shishi Xu
Juan Li
Nanwei Tong

Frontiers in Endocrinology

doi 10.3389/fendo.2020.599355

9,486 views
18 citations

Articles

The benefits of GLP1 receptors in cardiovascular diseases

SGLT2is vs. GLP1RAs Reduce Cardiovascular and All-Cause Mortality

Glucagon-like peptide-1 receptor agonists: new strategies and therapeutic targets to treat atherosclerotic cardiovascular disease

The potential of glucagon-like peptide-1 receptor agonists in heart failure

Exploring the comparative cardiovascular death benefits of sodium–glucose cotransporter 2 inhibitors in type 2 diabetes: a frequentist and Bayesian network meta-analysis-based scoring

Exposure–Response Analysis of Cardiovascular Outcome Trials With Incretin-Based Therapies

The Effects of DPP-4 Inhibitors, GLP-1RAs, and SGLT-2/1 Inhibitors on Heart Failure Outcomes in Diabetic Patients With and Without Heart Failure History: Insights From CVOTs and Drug Mechanism